Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study

Mette Reilev; Per Damkier; Lotte Rasmussen; Morten Olesen; Martin Thomsen Ernst; Rikke Mie Rishøj; Morten Rix Hansen; Anne Broe; Alexander Steenberg Dastrup; Maja Hellfritzsch; Sidsel Arnspang; Anton Pottegård; Jesper Hallas

doi:10.1177/1756283X17734116

Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study

Mette Reilev, Per Damkier, Lotte Rasmussen, Morten Olesen, Martin Thomsen Ernst, Rikke Mie Rishøj, Morten Rix Hansen, Anne Broe, Alexander Steenberg Dastrup, Maja Hellfritzsch, Sidsel Arnspang, Anton Pottegård, Jesper Hallas

Research output: Contribution to journal › Journal article › Research › peer-review

236 Downloads (Pure)

Abstract

Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.

Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.

Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.

Conclusions: We found no association between beta-blocker use and UGIB.

Original language	English
Journal	Therapeutic Advances in Gastroenterology
Volume	10
Issue number	12
Pages (from-to)	919-929
ISSN	1756-283X
DOIs	https://doi.org/10.1177/1756283X17734116
Publication status	Published - 2017

Keywords

Journal Article

Documents & Links

10.1177/1756283X17734116Licence: CC BY-NC

Use of beta-blockers and risk of serious upper gastrointestinal bleedingFinal published version, 94.9 KBLicence: CC BY-NC

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Reilev, M., Damkier, P., Rasmussen, L., Olesen, M., Thomsen Ernst, M., Rishøj, R. M., Rix Hansen, M., Broe, A., Dastrup, A. S., Hellfritzsch, M., Arnspang, S., Pottegård, A., & Hallas, J. (2017). Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study. Therapeutic Advances in Gastroenterology, 10(12), 919-929. https://doi.org/10.1177/1756283X17734116

@article{4e9f4a31023b4ea69afeb7c0e7dde8b1,

title = "Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study",

abstract = "Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95\% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.",

keywords = "Journal Article",

author = "Mette Reilev and Per Damkier and Lotte Rasmussen and Morten Olesen and \{Thomsen Ernst\}, Martin and Rish{\o}j, \{Rikke Mie\} and \{Rix Hansen\}, Morten and Anne Broe and Dastrup, \{Alexander Steenberg\} and Maja Hellfritzsch and Sidsel Arnspang and Anton Potteg{\aa}rd and Jesper Hallas",

year = "2017",

doi = "10.1177/1756283X17734116",

language = "English",

volume = "10",

pages = "919--929",

journal = "Therapeutic Advances in Gastroenterology",

issn = "1756-283X",

publisher = "SAGE Publications",

number = "12",

}

Reilev, M , Damkier, P , Rasmussen, L , Olesen, M , Thomsen Ernst, M, Rishøj, RM, Rix Hansen, M, Broe, A, Dastrup, AS, Hellfritzsch, M, Arnspang, S , Pottegård, A & Hallas, J 2017, 'Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study', Therapeutic Advances in Gastroenterology, vol. 10, no. 12, pp. 919-929. https://doi.org/10.1177/1756283X17734116

TY - JOUR

T1 - Use of beta-blockers and risk of serious upper gastrointestinal bleeding

T2 - a population-based case-control study

AU - Reilev, Mette

AU - Damkier, Per

AU - Rasmussen, Lotte

AU - Olesen, Morten

AU - Thomsen Ernst, Martin

AU - Rishøj, Rikke Mie

AU - Rix Hansen, Morten

AU - Broe, Anne

AU - Dastrup, Alexander Steenberg

AU - Hellfritzsch, Maja

AU - Arnspang, Sidsel

AU - Pottegård, Anton

AU - Hallas, Jesper

PY - 2017

Y1 - 2017

N2 - Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.

AB - Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.

KW - Journal Article

U2 - 10.1177/1756283X17734116

DO - 10.1177/1756283X17734116

M3 - Journal article

C2 - 29204187

SN - 1756-283X

VL - 10

SP - 919

EP - 929

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

IS - 12

ER -

Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study

Abstract

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this